Together, these several advantageous properties of ganetespib’s HSP90-targeting therapy for cancer emphasize the effectiveness and applicability of this cutting-edge molecular strategy and may serve as the foundation for further clinical research in this area. Here, HSP90AB1 is linked to cancer.